TOPIRAMATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H21NO8S
Molecular Weight	339.362
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2

InChI

InChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N

InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C12H21NO8S
Molecular Weight	339.362
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00273
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf

Topiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically. The precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAAreceptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions. Topiramate is used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Topiramate is sold under the brand name Topamax. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf	Inhibitor 8228	5.0 nM [Ki]
Carbonic anhydrase IV 33 Target ID: CHEMBL3729 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf	Inhibitor 8228	4.9 µM [Ki]
Carbonic anhydrase VII 36 Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26915563	Inhibitor 8228	0.9 nM [Ki]
Carbonic anhydrase XII 30 Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15686894	Inhibitor 8228	3.8 nM [Ki]
GABA receptor alpha-1 subunit 19 Target ID: CHEMBL1962 Sources: http://www.drugbank.ca/drugs/DB00273	Agonist 2662
Carbonic anhydrase VA 27 Target ID: CHEMBL4789 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18640037	Inhibitor 8228	63.0 nM [Ki]
Carbonic anhydrase VB 12 Target ID: CHEMBL3969 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18640037	Inhibitor 8228	30.0 nM [Ki]
Carbonic anhydrase XIII 10 Target ID: CHEMBL3912 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18640037	Inhibitor 8228	47.0 nM [Ki]
Sodium channel protein type I alpha subunit 15 Target ID: CHEMBL1845 Sources: http://www.drugbank.ca/drugs/DB00273	Inhibitor 8228
GABA-A receptor; anion channel 202 Target ID: CHEMBL2093872 Sources: http://www.drugbank.ca/drugs/DB00273 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf	Positive Allosteric Modulator 179
Glutamate receptor ionotropic kainate 25 Target ID: CHEMBL2109241 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf	Antagonist 2760

Conditions

Condition	Modality	Targets	Highest Phase	Product
Epilepsy 122 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf	Primary		Approved 8360	TOPAMAX Approved Use TOPAMAX is indicated for: Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache Launch Date 8.5129921E11
Migraine 103 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf	Preventing		Approved 8360	TOPAMAX Approved Use TOPAMAX is indicated for: Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache Launch Date 8.5129921E11

C_max

Value	Dose	Analyte	Population
6.98 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.46 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
1.63 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.38 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.73 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.68 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
350.3 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
311.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
57.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
59.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TOPIRAMATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
59% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	unknown, unknown		TOPIRAMATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1200 mg 1 times / day steady, oral MTD Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24861853	healthy, 23.3 years (range: 20–26 years) n = 8 Health Status: healthy Age Group: 23.3 years (range: 20–26 years) Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/24861853	Sources: https://pubmed.ncbi.nlm.nih.gov/24861853
4000 mg single, oral Overdose Dose: 4000 mg Route: oral Route: single Dose: 4000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19514879	unknown, 24 years n = 1 Health Status: unknown Age Group: 24 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/19514879	Sources: https://pubmed.ncbi.nlm.nih.gov/19514879
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	unhealthy, 6-15 years n = 77 Health Status: unhealthy Condition: Epilepsy Age Group: 6-15 years Population Size: 77 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Disc. AE: Attention concentration difficulty, Fever... AEs leading to discontinuation/dose reduction: Attention concentration difficulty (>=2) Fever (>=2) Flushing (>=2) Confusion (>=2) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Disc. AE: Memory impairment, Fatigue... AEs leading to discontinuation/dose reduction: Memory impairment (>=2) Fatigue (>=2) Asthenia (>=2) Insomnia (>=2) Somnolence (>=2) Paresthesia (>=2) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/24861853	unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/24861853	Disc. AE: Psychomotor retardation, Memory impairment... AEs leading to discontinuation/dose reduction: Psychomotor retardation (4%) Memory impairment (3.2%) Fatigue (3.2%) Confusion (3.1%) Somnolence (3.2%) Attention concentration difficulty (2.9%) Anorexia (2.7%) Depression (2.6%) Dizziness (2.5%) Weight decrease (2.5%) Nervousness (2.3%) Ataxia (2.1%) Paresthesia (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/24861853
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf	unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf	Disc. AE: Convulsions aggravated, Attention concentration difficulty... AEs leading to discontinuation/dose reduction: Convulsions aggravated (2.3%) Attention concentration difficulty (1.6%) Language disorder (1.3%) Personality disorder (1.3%) Somnolence (1.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
96 g single, oral Overdose Dose: 96 g Route: oral Route: single Dose: 96 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	unknown n = 1 Health Status: unknown Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Other AEs: Coma... Other AEs: Coma (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63631	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63631
ChemicalBook	CB7402630	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7402630
MolPort	MolPort-001-615-062	https://www.molport.com/shop/molecule-link/MolPort-001-615-062
Selleck Chemicals	Topiramate	http://www.selleckchem.com/products/Topiramate.html
ZINC	ZINC000095616603	http://zinc15.docking.org/substances/ZINC000095616603
eMolecules	29547217	https://www.emolecules.com/cgi-bin/more?vid=29547217
eMolecules	29548990	https://www.emolecules.com/cgi-bin/more?vid=29548990
eMolecules	594585	https://www.emolecules.com/cgi-bin/more?vid=594585

PubMed

Title	Date	PubMed








Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain.	1999 Apr	10323596
Cerebral edema with herniation during acetaminophen-induced fulminant hepatic failure.	2000 Jul	10915174
Comparative efficacy and tolerability of drug treatments for bipolar disorder.	2001	11580309
Management strategies for refractory localization-related seizures.	2001	11520319
Topiramate in posttraumatic stress disorder: preliminary clinical observations.	2001	11495099
The new generation of GABA enhancers. Potential in the treatment of epilepsy.	2001	11475940
Behavioural effects of the new anticonvulsants.	2001	11444724
Effects of antiepileptic drugs on cognition.	2001	11422358
Topiramate: a review of its use in childhood epilepsy.	2001	11354701
Topiramate rapidly raises brain GABA in epilepsy patients.	2001 Apr	11440351
[Cognitive impairments due to add-on therapy with topiramate].	2001 Apr	11320862
Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?	2001 Apr	11320687
Novel treatments for bipolar disorder.	2001 Apr	11281816
New-onset absence status epilepsy presenting as altered mental status in a pediatric patient.	2001 Apr	11275834
Newer antiepileptic drugs: advantages and disadvantages.	2001 Aug	11504596
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy.	2001 Dec	11738929
[Antiepileptic drugs and neuropathic pain].	2001 Feb 16-28	11333392
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).	2001 Jan	11137386
[Controversies about the new anti-epileptic drugs].	2001 Jan 16-31	11299481
Effect of tiagabine and topiramate on porphyrin metabolism in an in vivo model of porphyria.	2001 Jul	11484905
The role of new antiepileptic drugs.	2001 Jul	11474769
Effects of topiramate on cognition.	2001 Jul	11439970
Topiramate for self-mutilation in a patient with borderline personality disorder.	2001 Jun	11465678
The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments.	2001 Jun	11450180
Control of Tourette's syndrome with topiramate.	2001 Jun	11384920
Topiramate and metabolic acidosis in pediatric epilepsy.	2001 Mar	11442157
Cognitive changes during topiramate therapy.	2001 Mar	11288765
Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial.	2001 Mar	11248537
Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study.	2001 Mar-Apr	11307048
Topiramate relieves idiopathic and symptomatic trigeminal neuralgia.	2001 May	11398791
[Juvenile myoclonic epilepsy].	2001 May 16-31	11424054
Pharmacologic management of epilepsy in the elderly.	2001 May-Jun	11372907
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation.	2001 Nov	11673017
Re: Weight change with antipsychotic use.	2001 Sep	11582832
Postmarketing experience with topiramate and cognition.	2001 Sep	11580760
Topiramate blocks perinatal hypoxia-induced seizures in rat pups.	2001 Sep	11558793
Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma.	2001 Sep 15	11585128
Clinical and electroencephalographic effects of topiramate in patients with epilepsy and healthy volunteers.	2001 Sep-Oct	11586113
Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder.	2001 Sep-Oct	11553525
Treatment-resistant bipolar disorder.	2001 Winter	11280956

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dose: 400 mg orally per day in 2 divided doses of 200 mg each The dose should be achieved by titration: Week 1: 25 mg orally in the morning and 25 mg orally in the evening Week 2: 50 mg orally in the morning and 50 mg orally in the evening Week 3: 75 mg orally in the morning and 75 mg orally in the evening Week 4: 100 mg orally in the morning and 100 mg orally in the evening Week 5: 150 mg orally in the morning and 150 mg orally in the evening Week 6: 200 mg orally in the morning and 200 mg orally in the evening

Route of Administration: Oral

In Vitro Use Guide

0.3 to 10 uM topiramate 1 inhibited ATPA-evoked postsynaptic currents recorded from rat basolateral amygdala (BLA) interneurons

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:38:17 UTC 2023` Edited by `admin` on `Wed Jul 05 22:38:17 UTC 2023`
Record UNII	0H73WJJ391
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOPIRAMATE

Official Name

English

TOPIRAMATE [USP-RS]

Common Name

English

USL-255

Code

English

TOPIRAMATE [USP MONOGRAPH]

Common Name

English

TPM

Common Name

English

TOPINA

Brand Name

English

TOPOMAX

Brand Name

English

TOPAMAX

Brand Name

English

TOPIRAMATE [USAN]

Common Name

English

TOPIRAMATE [JAN]

Common Name

English

QUDEXY

Brand Name

English

Topiramate [WHO-DD]

Common Name

English

TOPIRAMATE [EP MONOGRAPH]

Common Name

English

EPITOMA

Brand Name

English

TOPIRAMATE [VANDF]

Common Name

English

TOPIMAX

Brand Name

English

EPITOMAX

Brand Name

English

SINCRONIL

Brand Name

English

TOPIRAMATE [MART.]

Common Name

English

TOPIRAMATE COMPONENT OF QSYMIA

Brand Name

English

TOPIRAMATE [INCI]

Common Name

English

TOPIRAMATE [MI]

Common Name

English

USL255

Code

English

.BETA.-D-FRUCTOPYRANOSE, 2,3:4,5-BIS-O-(1-METHYLETHYLIDENE)-, SULFAMATE

Common Name

English

TOPIRAMATE [HSDB]

Common Name

English

topiramate [INN]

Common Name

English

EPRONTIA

Brand Name

English

RWJ-17021-000

Code

English

TOPIRAMATE [USP IMPURITY]

Common Name

English

MCN-4853

Code

English

RWJ-17021

Code

English

QSYMIA COMPONENT TOPIRAMATE

Brand Name

English

TOPIRAMATE [ORANGE BOOK]

Common Name

English

(-)-TOPIRAMATE

Common Name

English

2,3:4,5-DI-O-ISOPROPYLIDENE-.BETA.-D-FRUCTOPYRANOSE SULFAMATE

Common Name

English

TOPAMAC

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264